WO1994004070A1 - Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths - Google Patents

Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths Download PDF

Info

Publication number
WO1994004070A1
WO1994004070A1 PCT/US1993/007539 US9307539W WO9404070A1 WO 1994004070 A1 WO1994004070 A1 WO 1994004070A1 US 9307539 W US9307539 W US 9307539W WO 9404070 A1 WO9404070 A1 WO 9404070A1
Authority
WO
WIPO (PCT)
Prior art keywords
wavelengths
wavelength
blood
light
analyte
Prior art date
Application number
PCT/US1993/007539
Other languages
French (fr)
Inventor
Richard H. Clarke
Qian Wang
Original Assignee
Angiomedics Ii, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiomedics Ii, Incorporated filed Critical Angiomedics Ii, Incorporated
Priority to AU48063/93A priority Critical patent/AU4806393A/en
Publication of WO1994004070A1 publication Critical patent/WO1994004070A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/02Details of sensors specially adapted for in-vivo measurements
    • A61B2562/0233Special features of optical sensors or probes classified in A61B5/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/04Arrangements of multiple sensors of the same type
    • A61B2562/043Arrangements of multiple sensors of the same type in a linear array

Definitions

  • the technical field of this invention is material analysis and, in particular, the invention relates to the detection and quantification of analytes in materials by measuring the absorption of near infrared light.
  • Material analysis especially the analysis of liquid materials for the presence of solutes, can be a tedious and complex task. In many instances, it would be more desirable to be able to analyze materials quickly, easily and non- invasively.
  • One example of such an application is blood analysis.
  • blood is analyzed by withdrawing a sample from the body of a subject and examining it, using one or more techniques, such as immunoassays, activity assays, chromatographic assays and spectrophotometric assays.
  • immunoassays activity assays
  • chromatographic assays chromatographic assays
  • spectrophotometric assays suffer from several common disadvantages.
  • One such disadvantage is that these tests are invasive and raise the risk of patient infection and discomfort. Also, such tests can be time-consuming. This time delay between when the blood is drawn and when the analysis is completed provides a window during which the subject's blood content may have changed, possibly leading to erroneous test results.
  • a further disadvantage to conventional blood testing techniques is that the people drawing and testing the blood sample are put at risk for exposure to infectious disease agents.
  • an analytic apparatus for non-invasively, quickly and continuously detecting and quantifying analytes in a blood sample. It is another object of this invention to provide a method and apparatus for non-invasive detection of blood-glucose levels but which avoids the problems of non-continuous test results, subject discomfort and potential technician exposure to infectious agents.
  • a blood sample is non-invasively illuminated through a patient's tissue, such as the skin, at a plurality of wavelengths, including a reference and a data wavelength, for a target analyte.
  • These wavelengths are preferably selected from the near infrared spectrum, and are also preferably closely spaced to each other in order to minimize interference from other solutes in the blood.
  • Non-invasive measurements of the absorption of light at such wavelengths are taken (e.g., by measuring reflectance or transmittance), and a non-invasive analysis of absorption ratios is performed for various sets of these wavelengths. Changes in the detected reflectance or transmittance ratios are then correlated with specific material properties, such as the concentration of glucose, urea or cholesterol in a subject's circulatory system.
  • the present invention eliminates (or at least reduces) the effect of light scattering caused by blood solutes other than the analyte as well as the scattering effects of background and patient-dependent factors (e.g., pigmentation, thickness and vascularization of the skin) that might otherwise interfere with accurate measurements.
  • two wavelengths are selected as close together as possible, to assure a narrow window, and the window is located at a relatively long wavelength, e.g., over 1000 nm.
  • glucose absorbance data is reliably obtained at about 1600 nm +/- 15 nm, and reliably evaluated when selected in combination with a reflectance reference wavelength in the close by range of 1630-1660 nm, the latter being relatively insensitive to glucose content.
  • a reference reading above the 1600 nm data point (e.g., in the 1630 to 1660 nm range) is preferable over a reference measurement below the data point (e.g., in the 1540 to 1570 nm range) because of urea and water measurement peaks at about 1500 nm can cause interference.
  • the absorption of light by other analytes at 1600 nm and in the 1630 to 1660 range is relatively low, or the differences are small, thereby minimizing interference due to such other analytes.
  • a reference reflectance reading may be obtained at about 1300 nm, as an alternative or supplemental reference reading. While the latter reference wavelength is further removed from 1600 nm, and typically will result in lower precision due to increased scattering effects, it provides an alternative or supplemental reference wavelength which will still yield favorable results.
  • cholesterol levels can be measured in a circulating bloodstream within a subject, by obtaining light absorbance data at about 1720 nm +/- 15 nm, or at about 2300 nm +/- 15 nm, in combination with a closely spaced reference wavelength, the latter being relatively insensitive to cholesterol content.
  • urea levels can be measured in a circulating bloodstream within a subject, by obtaining light absorbance data at about 1500 nm +/- 15 nm, in combination with a closely spaced reference wavelength, the latter being relatively insensitive to urea content.
  • near infrared or “near IR” is intended to encompass light in a spectrum ranging from about 1000 to about 2500 nm, more preferably from about 1300 to about 2300 nm, and, in some instances, most preferably from about 1500 to about 1800 nm.
  • the terms "closely spaced” or “narrow window” are intended to describe paired wavelengths for measurement of an analyte, with a first wavelength being chosen proximal to a near infrared (IR) absorption peak for the analyte which varies with concentration of the analyte (the data wavelength) and the a second (reference) wavelength being sufficiently removed from the first so that measurements of light absorption at this second wavelength are relatively insensitive to the concentration of the analyte and yet the second wavelength is sufficiently close to the first wavelength to minimize interference from scattering effects and the like.
  • the window bracketing these closely spaced wavelengths will be less than about 300 nm and preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.
  • the use of a narrow window also assures that non-analyte absorption effects as well as scattering effects are minimized.
  • an analytic apparatus and method employing a multi-wavelength illumination source, a wavelength- specific detector array and a reflection ratio analyzer.
  • the illumination source illuminates material sample at a plurality of discrete wavelengths selected from the near infrared region, in a narrow window as described above, e.g., less than about 300 nm or preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.
  • the detector array detects the IR light absorbed by the sample, converts the detected light into electrical signals indicative of the intensity of the reflected (or transmitted) light at each selected wavelength. These signals can then be processed by a absorption ratio analyzer.
  • the ratio analyzer then derives a ratio for at least two of the detected wavelengths, for example, in the case of glucose, selecting a reference wavelength at approximately 1630-1660 nanometers and a glucose data wavelength at approximately 1600 nanometers, such that the ratio can be compared with predetermined values to non-invasively detect the concentration of glucose in a subject's circulatory system.
  • the preferred embodiment By performing a ratio analysis in a narrowed window at longer wavelengths, the preferred embodiment eliminates background and patient- dependent (e.g., skin pigmentation, thickness and vascular) factors that might otherwise interfere with accurate measurements. Other wavelength combinations are also within the scope of the invention.
  • the illumination source further includes at least two laser diodes, producing light at distinct wavelengths, to illuminate the subject's skin with IR light at both a reference and a data wavelength. This embodiment is particularly well-suited to providing a system for detecting glucose in blood circulating through a surface vein, or in a nailbed of a finger, due to the penetration of near infrared wavelengths of light through human tissue.
  • the methods of the invention utilize the observation that analytes differentially absorb near IR light at various wavelengths and that data and reference wavelength can be chosen to quantify the presence of the analyte, non- invasive reflectance or transmittance measurements.
  • a surface vein in a human subject, or a fingernail bed can be illuminated with light at a first data wavelength, and a non-invasive reading is taken so as to establish a blood analyte level.
  • the vein or bed is also either concurrently or sequentially illuminated with light at a second reference wavelength and a second non-invasive reading is taken, so as to establish a baseline background value.
  • the ratio of these reflectance readings is compared to known (e.g., stored in a look-up table) ratios relating to known analyte levels, and an analyte level is thereby determined.
  • the present invention is an improvement over the prior art in that it can, with improved accuracy, non-invasively, quickly and easily detect and/or quantify blood analyte levels. In this way, the invention eliminates the problems of non-continuous data, subject discomfort and/or potential exposure to infectious diseases.
  • a single fiber can be used for transmission and detection of multiple interrogation wavelengths.
  • lasers are described as preferred light sources, other illumination means, including non- coherent, discrete wavelength light sources, can be employed.
  • FIG. 1 is a schematic block diagram of an analytic apparatus according to the invention
  • FIG. 2 is a schematic diagram of the apparatus according to the invention particularly adapted for non-invasive detection of analytes in a subject's blood;
  • FIG. 3 is a detailed view of a sampling head assembly of the apparatus of FIG. 2;
  • FIG. 3 A is a schematic view of an alternative apparatus according to the invention.
  • FIG. 4 is a more detailed illustration of an individual optical fiber and its connection to an illumination source and a detector element according to a reflection mode embodiment of the invention
  • FIG. 5 is a graph of the reflectance spectrum of glucose, illustrating the analytical techniques of the present invention.
  • FIG. 5 A is a graph of the reflectance of cholesterol over a spectrum of about 1000 to 2500 nm;
  • FIG. 6 is a graph of absorbance versus glucose concentration for illumination at 1586 nm for several concentrations of glucose
  • FIG. 7 is a graph of glucose absorbance in arbitrary units versus wavelength from about 1 100 to 2500 nm. for two samples (curve 1 and 2) having the same concentration of glucose in water, with one sample (curve 2) also including a scattering analyte; and
  • FIG. 8 is a graph of absorbance exhibited by albumin, glucose, urea, uric acid and cholesterol in a blood sample illuminated over the range of 1000 to 2500 nm.
  • FIG. 1 a schematic block diagram of an analytic apparatus 10 according to the invention is shown.
  • Apparatus 10 includes a multiple wavelength illumination source 12, a wavelength specific detector array 14, and a reflection ratio analyzer 16.
  • Illumination source 12 can be a single, multi-wavelength laser diode or a series of discrete diode elements, each emitting a distinct wavelength of light selected from the near infrared region to illuminate a blood sample 18 via optical path 20a.
  • illumination source 12 can be a broadband near IR emitter, emitting both the data and reference wavelengths as part of a broadband interrogation burst of IR light or radiation.
  • Detector array 14 detects light reflected (or transmitted) by sample 18 through optical path 20b.
  • the detector array 14 converts the reflected light into electrical signals indicative of the degree of abso ⁇ tion light at each wavelength and transfers the converted signals to the abso ⁇ tion ratio analyzer 16.
  • Analyzer 16 processes the electrical signals and derives an abso ⁇ tion (e.g., a reflection or transmittance) ratio for at least two of the wavelengths. Analyzer 16 then compares the calculated ratio with predetermined values to detect the concentration and/or presence of the analyte in the blood sample 18.
  • abso ⁇ tion e.g., a reflection or transmittance
  • laser diode elements 12a- 12f comprise a multiple wavelength illumination source 12, which provides light at a series of skin penetrating wavelengths.
  • Diode elements 12a-12f can each transmit a predetermined wavelength of light via corresponding optical fiber elements 24a-24f and sampling head 26, to vein segment 28 of wrist 30. (Alternatively, light at various wavelengths can be emitted by one multiple- wavelength laser diode and transmitted via a single optical fiber.) The discrete wavelengths of laser light automatically pass through the tissue of wrist 30 and illuminate the blood circulating in surface vein 28.
  • At least one of the diode elements 12a-12f can transmit interrogating radiation in a wavelength range of about 1600 nm in order to obtain glucose concentration data, and another of the diode elements 12a-12f can transmit radiation in at about 1630-1660 nm, or about 1540-1570 nm, to obtain glucose reference measurements. In some instances, it may also be preferable to take at least one further glucose reference reading (e.g., at about 1300 nm) using another of the diode elements 12a-12f to provide additional baseline data for analyte discrimination.
  • at least one further glucose reference reading e.g., at about 1300 nm
  • At least one of the diode elements 12a-12f can transmit interrogating radiation at a wavelength about 1720 nm and another of the diode elements 12a-12f can transmit radiation at 1600 or 1800 nm. In some instances, it may also be preferable to take at least one further reading using another of the diode elements 12a-12f to provide additional baseline data for analyte discrimination.
  • Other diode elements can be dedicated to the measurement of other analytes (such as cholesterol, urea or ureic acid, using similar pairs of closely spaced data and reference wavelengths, as described above).
  • each optical fiber element 24a-24f carries a reflected light signal having the same wavelength as the light originally transmitted along it.
  • Diode detectors 14a- 14f receive the reflected light from the optical fiber elements 24a-24f and convert these light waves into a series of electrical signals indicative of the intensity of each of the reflected wavelengths of light received from surface vein 28.
  • optical fiber element 14a can also carry reflected light of wavelength 1595 nm back to diode detector element 22a.
  • diode detector elements 14a- 14f transmit the electrical signals indicative of the intensity of the reflected light to reflection ratio analyzer 16 along electrical connection 32.
  • Analyzer 16 compares the electrical signals received from diode detector elements 14a-14f to derive a reflectance ratio for at least two of the transmitted wavelengths of light, such that the ratio can be compared to predetermined values to detect the presence of glucose or cholesterol in the blood flowing through vein 28. Analyzer 16 then can be employed to determine the presence and concentration of glucose or presence and concentration of cholesterol alone or along with other blood analytes.
  • FIG. 3 shows a more detailed view of the sampling head 26 of FIG. 2.
  • optical fiber elements 24a-24f of optical fiber bundle 24 are adapted to extend through a corresponding set of holes 32a-32f in the sampling head 26, thus, facilitating alignment of optical fiber elements 24a-24f along a surface vein or other vascular region.
  • Sampling head 26 also comprises taping flanges 34a and 34b located at opposed ends of sampling head 26, providing a means for affixing sampling head 26 above the surface.
  • FIG. 3 A shows an alternative embodiment of a sampling head 26 of FIG. 2.
  • Optical fiber elements 24'a-f of optical fiber bundle 24' coupled to source 12 are adapted to extend through a corresponding set of holes in the sampling head 26A, thus facilitating alignment of the optical fiber elements at the surface 42 of a finger 44 immediately above a nailbed 46.
  • the light from fibers 24'a-f is transmitted through the finger and abso ⁇ tion is measured by applying a detector 48 on the opposite side of the finger.
  • the detector 48 can employ a corresponding series of optical fibers 24"a-f and, optionally, a corresponding set of wavelength- specific filters 49 a-f, as shown, or, in a more simple embodiment, a broadband detector can be used and rely, for example, on sequential emissions of specific interrogation wavelengths by the illumination means.
  • the sampling head 26A and detector 48 can be attached to the fingertip by a clip 51, as shown, or by straps located at opposed ends of sampling head 26A, in a manner similar the attachment means of FIG. 3, to provide a means for affixing the apparatus about the finger. (In other transmittance measuring embodiments, the sampling head 26A and detector 48 can be disposed in other locations as well, such as an earlobe, toe or the like.)
  • FIG. 4 is a more detailed illustration of an individual optical fiber 24a and its connection to an illumination source 12a and a detector element 14a in a reflection-mode analysis system according to the invention. Since each of optical fiber elements 24a-24f is identically adapted, only optical fiber element 24a is shown.
  • Laser diode element 12a is connected to optical fiber element 24a via optical fiber element 36a through optical splitter 38a.
  • Diode detector element 14a is connected to optical fiber element 24a via optical fiber element 40a, also through optical splitter 38a.
  • Optical splitter element 38a (and corresponding elements 38b-38f, not shown) enables dual usage of optical fiber elements 24a-24f so that the light emitted by laser diode elements 12a- 12f and not absorbed by the tissue sample travels along the same optical fiber elements 24a-24f.
  • FIG. 5 is a graph of the reflectance spectrum of glucose.
  • the wavelength of the source light is shown along the x-axis and reflectance (in terms of log (1/R), where R is the intensity of the light reflected back from the blood) is shown along the y-axis in arbitrary units.
  • glucose shows a strong absorbance peak at about 1600 nm.
  • FIG. 5 A is a graph of the reflectance of cholesterol from 1000 to 2500 nm.
  • cholesterol has a reflectance peak at about 1720 nm and 2300 nm, which can be used as the wavelengths for collection of cholesterol reflectance or transmittance data.
  • the signal trails off substantially on either side of the peak, so that signal level differences even in this narrow window provide useful data for the above rationing process.
  • FIG. 6 is a graph illustrating the principles of the present invention applied to glucose concentration measurement.
  • FIG. 6 is a plot of absorbance of infrared radiation at about 1600 nm versus actual concentrations of glucose in an aqueous solution. The absorbance measurements were taken by irradiating samples through an excised dog artery wall to simulate in vivo conditions. As can be seen from the graph, the measured absorbance provides an accurate determination of glucose concentration in a linear fashion and over a wide range of concentrations.
  • the present invention is based on the recognition that there is a general class of scattering phenomena and abso ⁇ tion by other analytes which can affect reflectance (or transmittance) readings. It is further recognized that the particular combination of wavelengths selected for rationing can effect detection accuracy.
  • FIG. 7 is a graph of glucose absorbance for two aqueous samples having the same amount of glucose, but one loaded with a scattering analyte. The data is measured over a range of infra-red illumination of about 1000 - 2500 nm.
  • Curve 1 shows absorbance for glucose alone in water (no scatterer), and curve 2 shows the absorbance characteristics for glucose and a scatterer (yeast) in water.
  • the wavelength of the source light is shown along the x-axis ranging from about 1000-2500 nm.
  • the absorbance of light is shown along the y-axis.
  • the glucose absorbance value (s, s') is indicated at about 1600 nm and then an absorbance reference value is indicated at about 1650 nm (rl,rl') and at about 1100 nm (r2,r2').
  • the effect of scattering is demonstrated from FIG. 7 by comparing the divergence of the reference signal from the data signal for each reference datum, for each curve.
  • the first reference signal (rl) diverges from the glucose absorbance data signal (s) by about .0025 units
  • the second reference signal (r2) diverges from the data signal (s) by about .0048 units.
  • the first reference signal (rl 1 ) diverges from the data signal (s') by about .0022 units
  • the second reference signal (r2') diverges from the data signal (s') by about .0284 units, approximately an order of magnitude larger difference than that obtained using a closer reference wavelength.
  • FIG. 8 is a graph of absorbance exhibited by albumin, glucose, urea, uric acid and cholesterol in a blood sample illuminated over the range of 1000 to 2500 nm, and provides another analytical example of the invention, namely, an analysis for cholesterol in blood. At about 1720 nm and 2300, cholesterol reaches an abso ⁇ tion peak, while the other analytes are in a more gradual mode. After determination of the level of other analytes of interest (albumin, uric acid, glucose, urea) a subtractive process can be used to obtain the detection signal for glucose, cholesterol or any other analyte of interest.
  • analytes of interest albumin, uric acid, glucose, urea
  • the cholesterol data signal is obtained and is compared to the reference wavelength and a ratio is obtained by the rationing described above, and then the ratio is compared to data stored in a lookup table to obtain a cholesterol reading for the subject. If a narrow detection window of about 100 nm is used, e.g., 1720 compared to 1620 or 1820, for example, this has the benefit of substantially reducing scattering effects.
  • the present invention benefits from the recognition that there is a general class of scattering phenomena which can effect reflectance readings. These scattering phenomena are principally due to size issues, i.e., big molecules making up the skin, the blood, and the cells themselves. Other artifacts in the detected reflectance signals can arise from skin pigmentation and gross variations in blood constitution from patient to patient. Furthermore, given that scattering increases as wavelength shortens, we have selected a preferred narrow window, with the cholesterol absorbance wavelength at about 1720 nm or 2300 nm. The invention can therefore reduce scattering by selection of relatively long wavelengths and by selection of as narrow a window as possible. Nevertheless, where necessity dictates, such as where other analytes are present, other wavelengths in the near infrared range may also be used in useful practice of the invention.
  • these selected values exploit the foregoing properties of cholesterol by taking the ratio of light reflected from or transmitted by blood at a reference near infrared wavelength where cholesterol abso ⁇ tion is minimal, and at a data near infrared wavelength where reflectance or transmittance will be dependent on the concentration of cholesterol present in the irradiated region, with minimized effect of light scattering on the subsequent reflectance rationing.
  • the site of application of the invention has been described with respect to a vein, but also may be applied to the bed of a fingernail or other easily accessible areas where blood flow is adequate.
  • Light sources such as laser diodes or light-emitting diodes, at the preferred wavelengths disclosed herein may be used, either custom designed or as tuned or filtered in a conventional manner.
  • the invention may be embodied in other specific forms without departing from the spirit or the essential characteristics thereof.
  • the present embodiment is to be considered as illustrative and not restrictive.
  • the scope of the invention is indicated by the appended claims, rather than by the foregoing description, and all changes which come within the meaning and range of equivalent of the claims are therefor intended to be embraced therein.

Abstract

Systems and methods for non-invasive blood analysis are disclosed in which blood is illuminated at a plurality of discrete wavelengths selected from the near infrared spectrum. Measurements of the intensity of transmitted or reflected light at such wavelengths are taken, and an analysis of transmittance or reflectance ratios for various wavelengths is performed. Changes in the ratios can be correlated with the specific near infrared (IR) absorption peak for the analyte which varies with concentration of the analyte (the data wavelength) and a second (reference) wavelength being sufficiently removed from the first so that measurements of light absorption at this second wavelength are relatively insensitive to the concentration of the analyte and yet the second wavelength is sufficiently close to the first wavelength to minimize interference from scattering effects and the like. Typically, the window bracketing these closely spaced wavelengths will be less than about 300 nm and preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.

Description

NON-INVASIVE BLOOD ANALYSIS BY NEAR
INFRARED ABSORPTION MEASUREMENTS USING
TWO CLOSELY SPACED WAVELENGTHS
Background of the Invention
The technical field of this invention is material analysis and, in particular, the invention relates to the detection and quantification of analytes in materials by measuring the absorption of near infrared light.
Material analysis, especially the analysis of liquid materials for the presence of solutes, can be a tedious and complex task. In many instances, it would be more desirable to be able to analyze materials quickly, easily and non- invasively. One example of such an application is blood analysis.
Treatment of many medical disorders, such as diabetes and other hormonal or metabolic disorders, requires accurate blood analysis. Additionally, in some situations, repeated or even continuous blood monitoring is desirable, for example, when monitoring drug dosage changes or variations in metabolic factors, such as glucose or cholesterol.
Conventionally, blood is analyzed by withdrawing a sample from the body of a subject and examining it, using one or more techniques, such as immunoassays, activity assays, chromatographic assays and spectrophotometric assays. These conventional methods suffer from several common disadvantages. One such disadvantage is that these tests are invasive and raise the risk of patient infection and discomfort. Also, such tests can be time-consuming. This time delay between when the blood is drawn and when the analysis is completed provides a window during which the subject's blood content may have changed, possibly leading to erroneous test results. A further disadvantage to conventional blood testing techniques is that the people drawing and testing the blood sample are put at risk for exposure to infectious disease agents.
Accordingly, it is the object of the present invention to provide an analytic apparatus for non-invasively, quickly and continuously detecting and quantifying analytes in a blood sample. It is another object of this invention to provide a method and apparatus for non-invasive detection of blood-glucose levels but which avoids the problems of non-continuous test results, subject discomfort and potential technician exposure to infectious agents.
Summary of the Invention
Systems and methods for non-invasive blood analysis are disclosed in which a blood sample is non-invasively illuminated through a patient's tissue, such as the skin, at a plurality of wavelengths, including a reference and a data wavelength, for a target analyte. These wavelengths are preferably selected from the near infrared spectrum, and are also preferably closely spaced to each other in order to minimize interference from other solutes in the blood. Non-invasive measurements of the absorption of light at such wavelengths are taken (e.g., by measuring reflectance or transmittance), and a non-invasive analysis of absorption ratios is performed for various sets of these wavelengths. Changes in the detected reflectance or transmittance ratios are then correlated with specific material properties, such as the concentration of glucose, urea or cholesterol in a subject's circulatory system.
One problem in obtaining reliable blood-analyte data is that the light impinged on the sample is scattered by various local properties of the subject. However, by performing a ratio analysis in a narrow window, the present invention eliminates (or at least reduces) the effect of light scattering caused by blood solutes other than the analyte as well as the scattering effects of background and patient-dependent factors (e.g., pigmentation, thickness and vascularization of the skin) that might otherwise interfere with accurate measurements.
It has been discovered that particular advantages can be obtained when closely-spaced data and reference wavelengths are selected, because when greater distances separate the analyte data wavelength from the reference wavelength, the effects of scattering on the measured ratio typically will be larger and more erratic. Thus, having a narrow detection window within which all the measurements are taken can limit the range of variation and, therefore, the effect of these phenomena, yielding a more accurate determination of in vivo blood- analyte levels.
Furthermore, it has also been discovered that scattering increases as wavelength approaches the visible light range. Therefore, in practice of the invention, two wavelengths are selected as close together as possible, to assure a narrow window, and the window is located at a relatively long wavelength, e.g., over 1000 nm. For example, to measure glucose levels in a circulating bloodstream within a subject, glucose absorbance data is reliably obtained at about 1600 nm +/- 15 nm, and reliably evaluated when selected in combination with a reflectance reference wavelength in the close by range of 1630-1660 nm, the latter being relatively insensitive to glucose content. In the case of glucose measurement, a reference reading above the 1600 nm data point (e.g., in the 1630 to 1660 nm range) is preferable over a reference measurement below the data point (e.g., in the 1540 to 1570 nm range) because of urea and water measurement peaks at about 1500 nm can cause interference. The absorption of light by other analytes at 1600 nm and in the 1630 to 1660 range is relatively low, or the differences are small, thereby minimizing interference due to such other analytes.
In the event that problems are encountered in measuring glucose in this range, then a reference reflectance reading may be obtained at about 1300 nm, as an alternative or supplemental reference reading. While the latter reference wavelength is further removed from 1600 nm, and typically will result in lower precision due to increased scattering effects, it provides an alternative or supplemental reference wavelength which will still yield favorable results.
In another example of the invention, cholesterol levels can be measured in a circulating bloodstream within a subject, by obtaining light absorbance data at about 1720 nm +/- 15 nm, or at about 2300 nm +/- 15 nm, in combination with a closely spaced reference wavelength, the latter being relatively insensitive to cholesterol content.
In yet another example of the invention, urea levels can be measured in a circulating bloodstream within a subject, by obtaining light absorbance data at about 1500 nm +/- 15 nm, in combination with a closely spaced reference wavelength, the latter being relatively insensitive to urea content.
As used herein the term "near infrared" or "near IR" is intended to encompass light in a spectrum ranging from about 1000 to about 2500 nm, more preferably from about 1300 to about 2300 nm, and, in some instances, most preferably from about 1500 to about 1800 nm. As used herein the terms "closely spaced" or "narrow window" are intended to describe paired wavelengths for measurement of an analyte, with a first wavelength being chosen proximal to a near infrared (IR) absorption peak for the analyte which varies with concentration of the analyte (the data wavelength) and the a second (reference) wavelength being sufficiently removed from the first so that measurements of light absorption at this second wavelength are relatively insensitive to the concentration of the analyte and yet the second wavelength is sufficiently close to the first wavelength to minimize interference from scattering effects and the like. Typically, the window bracketing these closely spaced wavelengths will be less than about 300 nm and preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.
By choosing a data wavelength that is highly specific for a particular analyte (i.e., with no competing nearby absorption peaks), the use of a narrow window also assures that non-analyte absorption effects as well as scattering effects are minimized.
In another aspect of the invention, an analytic apparatus and method are described employing a multi-wavelength illumination source, a wavelength- specific detector array and a reflection ratio analyzer. The illumination source illuminates material sample at a plurality of discrete wavelengths selected from the near infrared region, in a narrow window as described above, e.g., less than about 300 nm or preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.
The detector array detects the IR light absorbed by the sample, converts the detected light into electrical signals indicative of the intensity of the reflected (or transmitted) light at each selected wavelength. These signals can then be processed by a absorption ratio analyzer. The ratio analyzer then derives a ratio for at least two of the detected wavelengths, for example, in the case of glucose, selecting a reference wavelength at approximately 1630-1660 nanometers and a glucose data wavelength at approximately 1600 nanometers, such that the ratio can be compared with predetermined values to non-invasively detect the concentration of glucose in a subject's circulatory system.
By performing a ratio analysis in a narrowed window at longer wavelengths, the preferred embodiment eliminates background and patient- dependent (e.g., skin pigmentation, thickness and vascular) factors that might otherwise interfere with accurate measurements. Other wavelength combinations are also within the scope of the invention. In one particular embodiment of the invention, the illumination source further includes at least two laser diodes, producing light at distinct wavelengths, to illuminate the subject's skin with IR light at both a reference and a data wavelength. This embodiment is particularly well-suited to providing a system for detecting glucose in blood circulating through a surface vein, or in a nailbed of a finger, due to the penetration of near infrared wavelengths of light through human tissue.
The methods of the invention utilize the observation that analytes differentially absorb near IR light at various wavelengths and that data and reference wavelength can be chosen to quantify the presence of the analyte, non- invasive reflectance or transmittance measurements. For example, a surface vein in a human subject, or a fingernail bed, can be illuminated with light at a first data wavelength, and a non-invasive reading is taken so as to establish a blood analyte level. The vein or bed is also either concurrently or sequentially illuminated with light at a second reference wavelength and a second non-invasive reading is taken, so as to establish a baseline background value. The ratio of these reflectance readings is compared to known (e.g., stored in a look-up table) ratios relating to known analyte levels, and an analyte level is thereby determined.
The present invention is an improvement over the prior art in that it can, with improved accuracy, non-invasively, quickly and easily detect and/or quantify blood analyte levels. In this way, the invention eliminates the problems of non-continuous data, subject discomfort and/or potential exposure to infectious diseases.
The invention will next be described in connection with certain preferred embodiments; however, it should be clear that various additions, subtractions and modifications can be made without departing from the spirit or scope of the invention. For example, although the invention is illustrated in connection with a blood analysis system, various alternative embodiments can also be devised. Furthermore, while reflectance measurements are primarily discussed, transmittance measurements may be employed in a similar manner as an alternative in practice of the invention. Although the illustrated embodiment shows a system with a fiber optic bundle for delivery of six distinct wavelengths of light, it should be clear that the number of interrogation wavelengths, the size and shape of the sampling head, and the means for transmitting the light to and from the sample, can be varied to meet particular needs and applications. For example, in monitoring blood sugar levels, as few as two wavelengths may be used to measure the glucose concentration. Moreover, a single fiber can be used for transmission and detection of multiple interrogation wavelengths. Additionally, although lasers are described as preferred light sources, other illumination means, including non- coherent, discrete wavelength light sources, can be employed.
Brief Description of the Drawings
FIG. 1 is a schematic block diagram of an analytic apparatus according to the invention;
FIG. 2 is a schematic diagram of the apparatus according to the invention particularly adapted for non-invasive detection of analytes in a subject's blood;
FIG. 3 is a detailed view of a sampling head assembly of the apparatus of FIG. 2;
FIG. 3 A is a schematic view of an alternative apparatus according to the invention;
FIG. 4 is a more detailed illustration of an individual optical fiber and its connection to an illumination source and a detector element according to a reflection mode embodiment of the invention;
FIG. 5 is a graph of the reflectance spectrum of glucose, illustrating the analytical techniques of the present invention;
FIG. 5 A is a graph of the reflectance of cholesterol over a spectrum of about 1000 to 2500 nm;
FIG. 6 is a graph of absorbance versus glucose concentration for illumination at 1586 nm for several concentrations of glucose;
FIG. 7 is a graph of glucose absorbance in arbitrary units versus wavelength from about 1 100 to 2500 nm. for two samples (curve 1 and 2) having the same concentration of glucose in water, with one sample (curve 2) also including a scattering analyte; and
FIG. 8 is a graph of absorbance exhibited by albumin, glucose, urea, uric acid and cholesterol in a blood sample illuminated over the range of 1000 to 2500 nm. Detailed Description
In FIG. 1, a schematic block diagram of an analytic apparatus 10 according to the invention is shown. Apparatus 10 includes a multiple wavelength illumination source 12, a wavelength specific detector array 14, and a reflection ratio analyzer 16.
Illumination source 12 can be a single, multi-wavelength laser diode or a series of discrete diode elements, each emitting a distinct wavelength of light selected from the near infrared region to illuminate a blood sample 18 via optical path 20a. In some applications, illumination source 12 can be a broadband near IR emitter, emitting both the data and reference wavelengths as part of a broadband interrogation burst of IR light or radiation.
Detector array 14 detects light reflected (or transmitted) by sample 18 through optical path 20b. The detector array 14 converts the reflected light into electrical signals indicative of the degree of absoφtion light at each wavelength and transfers the converted signals to the absoφtion ratio analyzer 16. Analyzer 16 processes the electrical signals and derives an absoφtion (e.g., a reflection or transmittance) ratio for at least two of the wavelengths. Analyzer 16 then compares the calculated ratio with predetermined values to detect the concentration and/or presence of the analyte in the blood sample 18.
An embodiment of analytic apparatus 10 particularly adapted to provide reflective measurements of analytes in blood circulating through a surface vein is shown in FIG. 2. As can be seen from FIG. 2, laser diode elements 12a- 12f comprise a multiple wavelength illumination source 12, which provides light at a series of skin penetrating wavelengths. Diode elements 12a-12f can each transmit a predetermined wavelength of light via corresponding optical fiber elements 24a-24f and sampling head 26, to vein segment 28 of wrist 30. (Alternatively, light at various wavelengths can be emitted by one multiple- wavelength laser diode and transmitted via a single optical fiber.) The discrete wavelengths of laser light automatically pass through the tissue of wrist 30 and illuminate the blood circulating in surface vein 28. For example, at least one of the diode elements 12a-12f can transmit interrogating radiation in a wavelength range of about 1600 nm in order to obtain glucose concentration data, and another of the diode elements 12a-12f can transmit radiation in at about 1630-1660 nm, or about 1540-1570 nm, to obtain glucose reference measurements. In some instances, it may also be preferable to take at least one further glucose reference reading (e.g., at about 1300 nm) using another of the diode elements 12a-12f to provide additional baseline data for analyte discrimination.
In another example, at least one of the diode elements 12a-12f can transmit interrogating radiation at a wavelength about 1720 nm and another of the diode elements 12a-12f can transmit radiation at 1600 or 1800 nm. In some instances, it may also be preferable to take at least one further reading using another of the diode elements 12a-12f to provide additional baseline data for analyte discrimination. Other diode elements can be dedicated to the measurement of other analytes (such as cholesterol, urea or ureic acid, using similar pairs of closely spaced data and reference wavelengths, as described above).
Following irradiation by the diode elements 12a- 12f, a fraction of the transmitted light is reflected back from the blood circulating in surface vein 28 along optical fiber elements 24a-24f. (In one embodiment, each optical fiber element 24a-24f carries a reflected light signal having the same wavelength as the light originally transmitted along it.) Diode detectors 14a- 14f receive the reflected light from the optical fiber elements 24a-24f and convert these light waves into a series of electrical signals indicative of the intensity of each of the reflected wavelengths of light received from surface vein 28. For example, if laser diode element 12a originally transmitted light of wavelength 1595 nm (a glucose data measurement wavelength) along optical fiber element 14a, then optical fiber element 14a can also carry reflected light of wavelength 1595 nm back to diode detector element 22a. As shown in FIG. 2, diode detector elements 14a- 14f transmit the electrical signals indicative of the intensity of the reflected light to reflection ratio analyzer 16 along electrical connection 32. Analyzer 16 compares the electrical signals received from diode detector elements 14a-14f to derive a reflectance ratio for at least two of the transmitted wavelengths of light, such that the ratio can be compared to predetermined values to detect the presence of glucose or cholesterol in the blood flowing through vein 28. Analyzer 16 then can be employed to determine the presence and concentration of glucose or presence and concentration of cholesterol alone or along with other blood analytes.
FIG. 3 shows a more detailed view of the sampling head 26 of FIG. 2.
As can be seen from FIG. 3, optical fiber elements 24a-24f of optical fiber bundle 24 are adapted to extend through a corresponding set of holes 32a-32f in the sampling head 26, thus, facilitating alignment of optical fiber elements 24a-24f along a surface vein or other vascular region. Sampling head 26 also comprises taping flanges 34a and 34b located at opposed ends of sampling head 26, providing a means for affixing sampling head 26 above the surface.
FIG. 3 A shows an alternative embodiment of a sampling head 26 of FIG. 2. Optical fiber elements 24'a-f of optical fiber bundle 24' coupled to source 12 are adapted to extend through a corresponding set of holes in the sampling head 26A, thus facilitating alignment of the optical fiber elements at the surface 42 of a finger 44 immediately above a nailbed 46. The light from fibers 24'a-f is transmitted through the finger and absoφtion is measured by applying a detector 48 on the opposite side of the finger. The detector 48 can employ a corresponding series of optical fibers 24"a-f and, optionally, a corresponding set of wavelength- specific filters 49 a-f, as shown, or, in a more simple embodiment, a broadband detector can be used and rely, for example, on sequential emissions of specific interrogation wavelengths by the illumination means.
The sampling head 26A and detector 48 can be attached to the fingertip by a clip 51, as shown, or by straps located at opposed ends of sampling head 26A, in a manner similar the attachment means of FIG. 3, to provide a means for affixing the apparatus about the finger. (In other transmittance measuring embodiments, the sampling head 26A and detector 48 can be disposed in other locations as well, such as an earlobe, toe or the like.) FIG. 4 is a more detailed illustration of an individual optical fiber 24a and its connection to an illumination source 12a and a detector element 14a in a reflection-mode analysis system according to the invention. Since each of optical fiber elements 24a-24f is identically adapted, only optical fiber element 24a is shown. Laser diode element 12a is connected to optical fiber element 24a via optical fiber element 36a through optical splitter 38a. Diode detector element 14a is connected to optical fiber element 24a via optical fiber element 40a, also through optical splitter 38a. Optical splitter element 38a (and corresponding elements 38b-38f, not shown) enables dual usage of optical fiber elements 24a-24f so that the light emitted by laser diode elements 12a- 12f and not absorbed by the tissue sample travels along the same optical fiber elements 24a-24f.
For example, in blood sugar analysis, it has been observed that glucose has peaks in the near infrared that are in well-defined spectral regions and differentiable from the blood background. FIG. 5 is a graph of the reflectance spectrum of glucose. The wavelength of the source light is shown along the x-axis and reflectance (in terms of log (1/R), where R is the intensity of the light reflected back from the blood) is shown along the y-axis in arbitrary units. As shown in FIG. 5, glucose shows a strong absorbance peak at about 1600 nm.
FIG. 5 A is a graph of the reflectance of cholesterol from 1000 to 2500 nm. As can be seen, cholesterol has a reflectance peak at about 1720 nm and 2300 nm, which can be used as the wavelengths for collection of cholesterol reflectance or transmittance data. The signal trails off substantially on either side of the peak, so that signal level differences even in this narrow window provide useful data for the above rationing process.
FIG. 6 is a graph illustrating the principles of the present invention applied to glucose concentration measurement. FIG. 6 is a plot of absorbance of infrared radiation at about 1600 nm versus actual concentrations of glucose in an aqueous solution. The absorbance measurements were taken by irradiating samples through an excised dog artery wall to simulate in vivo conditions. As can be seen from the graph, the measured absorbance provides an accurate determination of glucose concentration in a linear fashion and over a wide range of concentrations. The present invention is based on the recognition that there is a general class of scattering phenomena and absoφtion by other analytes which can affect reflectance (or transmittance) readings. It is further recognized that the particular combination of wavelengths selected for rationing can effect detection accuracy. This is true because selection of a narrow window for obtaining all reflectance/absorbance data has the benefit of canceling out the effect of light scattering and non-specific absoφtion. These scattering phenomena are principally due to size issues, i.e., big molecules making up the skin, the blood, and the cells themselves. Other artifacts in the detected reflectance signals can arise from skin pigmentation and gross variations in blood constitution from patient to patient.
FIG. 7 is a graph of glucose absorbance for two aqueous samples having the same amount of glucose, but one loaded with a scattering analyte. The data is measured over a range of infra-red illumination of about 1000 - 2500 nm. Curve 1 shows absorbance for glucose alone in water (no scatterer), and curve 2 shows the absorbance characteristics for glucose and a scatterer (yeast) in water. The wavelength of the source light is shown along the x-axis ranging from about 1000-2500 nm. The absorbance of light is shown along the y-axis. For curves 1 and 2, respectively, the glucose absorbance value (s, s') is indicated at about 1600 nm and then an absorbance reference value is indicated at about 1650 nm (rl,rl') and at about 1100 nm (r2,r2').
The effect of scattering is demonstrated from FIG. 7 by comparing the divergence of the reference signal from the data signal for each reference datum, for each curve. For glucose in water (curve 1), the first reference signal (rl) diverges from the glucose absorbance data signal (s) by about .0025 units, and the second reference signal (r2) diverges from the data signal (s) by about .0048 units. For glucose and yeast in water, the first reference signal (rl1) diverges from the data signal (s') by about .0022 units, and the second reference signal (r2') diverges from the data signal (s') by about .0284 units, approximately an order of magnitude larger difference than that obtained using a closer reference wavelength. In particular, it should be noted that the closer reference differences (q-S] and r'j-s'j) deviate insignificantly in the two systems despite the large differences in scattering capacity. This experiment therefore demonstrates not only the substantial variation in readings caused by the presence of scatterers in a blood sample compared to readings for samples without scatterers, but also shows that by selecting the reflectance reference signal wavelength very close to the glucose absorbance data signal wavelength minimizes the effect of scattering. Similar results are obtainable for other analytes, such as cholesterol, urea and uric acid.
Furthermore, given that scattering increases as wavelength decreases, we have selected a preferred narrow window, with the glucose absorbance wavelength at about 1600 nm and the reference signal taken at about 1630-1660 nm. This selection therefore reduces scattering by selection of relatively long wavelengths and by the narrowness of the 1600-1660 nm window. These selected values exploit the foregoing properties of glucose by taking the ratio of light reflected from blood at a first near infrared wavelength where glucose absoφtion is minimal, and at a second, wavelength where reflectance will be dependent on the concentration of glucose present in the irradiated region, with minimized effect of light scattering on the subsequent absoφtion rationing.
FIG. 8 is a graph of absorbance exhibited by albumin, glucose, urea, uric acid and cholesterol in a blood sample illuminated over the range of 1000 to 2500 nm, and provides another analytical example of the invention, namely, an analysis for cholesterol in blood. At about 1720 nm and 2300, cholesterol reaches an absoφtion peak, while the other analytes are in a more gradual mode. After determination of the level of other analytes of interest (albumin, uric acid, glucose, urea) a subtractive process can be used to obtain the detection signal for glucose, cholesterol or any other analyte of interest.
The cholesterol data signal is obtained and is compared to the reference wavelength and a ratio is obtained by the rationing described above, and then the ratio is compared to data stored in a lookup table to obtain a cholesterol reading for the subject. If a narrow detection window of about 100 nm is used, e.g., 1720 compared to 1620 or 1820, for example, this has the benefit of substantially reducing scattering effects.
Thus, the present invention benefits from the recognition that there is a general class of scattering phenomena which can effect reflectance readings. These scattering phenomena are principally due to size issues, i.e., big molecules making up the skin, the blood, and the cells themselves. Other artifacts in the detected reflectance signals can arise from skin pigmentation and gross variations in blood constitution from patient to patient. Furthermore, given that scattering increases as wavelength shortens, we have selected a preferred narrow window, with the cholesterol absorbance wavelength at about 1720 nm or 2300 nm. The invention can therefore reduce scattering by selection of relatively long wavelengths and by selection of as narrow a window as possible. Nevertheless, where necessity dictates, such as where other analytes are present, other wavelengths in the near infrared range may also be used in useful practice of the invention.
In view of the above, these selected values exploit the foregoing properties of cholesterol by taking the ratio of light reflected from or transmitted by blood at a reference near infrared wavelength where cholesterol absoφtion is minimal, and at a data near infrared wavelength where reflectance or transmittance will be dependent on the concentration of cholesterol present in the irradiated region, with minimized effect of light scattering on the subsequent reflectance rationing.
The foregoing embodiments have been described with respect to reflectance; however, they are equally operable with measurement of transmittance.
The site of application of the invention has been described with respect to a vein, but also may be applied to the bed of a fingernail or other easily accessible areas where blood flow is adequate.
Light sources, such as laser diodes or light-emitting diodes, at the preferred wavelengths disclosed herein may be used, either custom designed or as tuned or filtered in a conventional manner. As indicated above, the invention may be embodied in other specific forms without departing from the spirit or the essential characteristics thereof. The present embodiment is to be considered as illustrative and not restrictive. The scope of the invention is indicated by the appended claims, rather than by the foregoing description, and all changes which come within the meaning and range of equivalent of the claims are therefor intended to be embraced therein.

Claims

What is claimed is:
1. A blood-analyte detection apparatus comprising:
infrared illumination means for non-invasively illuminating an in vivo blood sample in a patient at least two wavelengths in the near infrared spectrum;
detector means for non-invasively measuring light absorbed by said sample at least a first data wavelength and a second reference wavelength, and for converting said detected light into electrical signals, said signals being indicative of the intensity of said detected light at each wavelength;
the detector means further characterized as measuring light absoφtion at two closely-spaced wavelengths said first and second wavelengths spaced by less than about 60 nanometers in order to minimize inference from extraneous factors.
2. The apparatus of claim 1 wherein the illumination means is broadband infrared emitter.
3. The apparatus of claim 1 wherein the illumination means comprises a plurality of discrete IR radiation sources emitting light at different wavelengths in the near infrared spectrum.
4. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1000 to about 2500 nm.
5. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1300 to about 2300 nm.
6. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1500 to about 1800 nm.
7. The apparatus of claim 1 wherein said detector means detects the reflectance of said light upon said sample.
8. The apparatus of claim 1 wherein said detector means detects the transmittance of said light by said sample.
9. The apparatus of claim 1 wherein the detector further comprises a plurality of wavelength specific filters.
10. The apparatus of claim 1 wherein said first and second wavelengths are separated by less than about 30 nm.
11. The apparatus of claim 1 wherein one of said wavelengths is about 1600 nm for generating an analyte data signal and another of said wavelengths is about 1630-1660 for generation of a reference signal.
12. The apparatus of claim 1 wherein one of said wavelengths is about 1300 nm for generating a reference signal.
13. The apparatus of claim 1 wherein one of said wavelengths is about 1720 nm for generating an analyte data signal and another of said wavelengths is about 1620 nm or 1820 nm for generation of a reference signal.
14. The apparatus of claim 1 wherein one of said wavelengths is about 2300 nm for generating an analyte data signal and another of said wavelengths is about 2200 nm or 2400 nm for generation of a reference signal.
15. The apparatus of claim 1 wherein the apparatus further comprises an analyzing means for receiving and comparing said electrical signals to derive a detection ratio for at least two of said wavelengths, such that said ratio can be compared with predetermined values associated with known blood-analyte concentrations so as to detect the analyte level in said sample.
16. A method for detecting an analyte in a blood sample, comprising the steps of:
illuminating a source of blood non-invasively through the tissue of a subject at a plurality of wavelengths within a narrow window selected in the near infrared spectrum;
detecting light effected by said blood and converting said detected light into electrical signals indicative of the intensity of said effected light at a plurality of wavelengths selected from the near infrared spectrum, including a first data wavelength separated by less than about 60 nanometers;
analyzing said electrical signals to derive a ratio for at least two of said wavelengths; and
comparing said ratio to a predetermined value to detect the presence of an analyte in said blood.
17. The method of claim 16 wherein said first and second wavelengths are separated by less than about 30 nm.
18. The method of claim 16 wherein said detected light is a measure of the reflectance of said blood.
19. The method of claim 16 wherein said detected light is a measure of the transmittance of said blood.
20. The method of claim 16 wherein said tissue is skin.
21. The method of claim 16 wherein said tissue is in a nailbed.
22. The method of claim 16 wherein said tissue includes a vein.
PCT/US1993/007539 1992-08-14 1993-08-11 Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths WO1994004070A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48063/93A AU4806393A (en) 1992-08-14 1993-08-11 Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/930,070 US5222495A (en) 1990-02-02 1992-08-14 Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths
US07/930,070 1992-08-14

Publications (1)

Publication Number Publication Date
WO1994004070A1 true WO1994004070A1 (en) 1994-03-03

Family

ID=25458884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007539 WO1994004070A1 (en) 1992-08-14 1993-08-11 Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths

Country Status (3)

Country Link
US (1) US5222495A (en)
AU (1) AU4806393A (en)
WO (1) WO1994004070A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721521A1 (en) * 1994-06-27 1995-12-29 Commissariat Energie Atomique Automatic micro-doser medication dispenser device and intelligent dosing set using this device.
EP0700660A1 (en) * 1994-03-14 1996-03-13 Sony Corporation Blood sugar level measuring apparatus
GB2328279A (en) * 1997-08-12 1999-02-17 Abbott Lab Three wavelength in-vivo analyte detector
DE19612425C2 (en) * 1995-03-31 2000-08-31 Nihon Kohden Corp Apparatus for measuring hemoglobin concentration
WO2001037722A1 (en) * 1999-11-23 2001-05-31 Forskningscenter Risø A non-invasive method for the measurement of body fluid analytes
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
US7356365B2 (en) 2003-07-09 2008-04-08 Glucolight Corporation Method and apparatus for tissue oximetry
US7510849B2 (en) 2004-01-29 2009-03-31 Glucolight Corporation OCT based method for diagnosis and therapy
WO2012005696A1 (en) * 2010-07-08 2012-01-12 Glucostats System Pte Ltd Apparatus and method for predicting a parameter in the blood stream of a subject
US9060721B2 (en) 2008-03-04 2015-06-23 Glt Acquisition Corp. Flowometry in optical coherence tomography for analyte level estimation
US9078560B2 (en) 2004-08-11 2015-07-14 Glt Acquisition Corp. Method for data reduction and calibration of an OCT-based physiological monitor
US9554737B2 (en) 2004-08-11 2017-01-31 Masimo Corporation Noninvasively measuring analyte levels in a subject
RU2770566C1 (en) * 2021-01-15 2022-04-18 ООО "НПП Волга" Method for non-invasive determination of the content of lipids in a person

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
US6549795B1 (en) 1991-05-16 2003-04-15 Non-Invasive Technology, Inc. Spectrophotometer for tissue examination
ATE172623T1 (en) * 1991-12-17 1998-11-15 Dynamics Imaging Inc METHOD AND DEVICE FOR DIAGNOSING LIVING ORGANISMS
US6785568B2 (en) * 1992-05-18 2004-08-31 Non-Invasive Technology Inc. Transcranial examination of the brain
US5792050A (en) * 1992-07-06 1998-08-11 Alam; Mary K. Near-infrared noninvasive spectroscopic determination of pH
US5699797A (en) * 1992-10-05 1997-12-23 Dynamics Imaging, Inc. Method of investigation of microcirculation functional dynamics of physiological liquids in skin and apparatus for its realization
US5379764A (en) * 1992-12-09 1995-01-10 Diasense, Inc. Non-invasive determination of analyte concentration in body of mammals
US6002958A (en) * 1992-12-24 1999-12-14 Dynamics Imaging, Inc. Method and apparatus for diagnostics of internal organs
US5438985A (en) * 1993-01-25 1995-08-08 Synectics Medical, Incorporated Ambulatory recording of the presence and activity of substances in gastro-intestinal compartments
US5747789A (en) * 1993-12-01 1998-05-05 Dynamics Imaging, Inc. Method for investigation of distribution of physiological components in human body tissues and apparatus for its realization
US5865743A (en) * 1994-02-23 1999-02-02 Dynamics Imaging, Inc. Method of living organism multimodal functional mapping
US6192262B1 (en) 1994-02-23 2001-02-20 Dobi Medical Systems, Llc Method of living organism multimodal functional mapping
US5730133A (en) * 1994-05-20 1998-03-24 Dynamics Imaging, Inc. Optical functional mamoscope
US5685313A (en) * 1994-05-31 1997-11-11 Brain Monitor Ltd. Tissue monitor
US5747806A (en) * 1996-02-02 1998-05-05 Instrumentation Metrics, Inc Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy
US6040578A (en) * 1996-02-02 2000-03-21 Instrumentation Metrics, Inc. Method and apparatus for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6018673A (en) * 1996-10-10 2000-01-25 Nellcor Puritan Bennett Incorporated Motion compatible sensor for non-invasive optical blood analysis
US5910109A (en) * 1997-02-20 1999-06-08 Emerging Technology Systems, Llc Non-invasive glucose measuring device and method for measuring blood glucose
US6628809B1 (en) 1999-10-08 2003-09-30 Lumidigm, Inc. Apparatus and method for identification of individuals by near-infrared spectrum
US7890158B2 (en) 2001-06-05 2011-02-15 Lumidigm, Inc. Apparatus and method of biometric determination using specialized optical spectroscopy systems
US6305804B1 (en) 1999-03-25 2001-10-23 Fovioptics, Inc. Non-invasive measurement of blood component using retinal imaging
KR100675706B1 (en) * 1999-08-26 2007-02-01 아이센스 아게 Ocular Analyte Sensor
US7904139B2 (en) * 1999-08-26 2011-03-08 Non-Invasive Technology Inc. Optical examination of biological tissue using non-contact irradiation and detection
US7840257B2 (en) 2003-01-04 2010-11-23 Non Invasive Technology, Inc. Examination of biological tissue using non-contact optical probes
US6216022B1 (en) 2000-06-22 2001-04-10 Biosafe Laboratories, Inc. Implantable optical measurement device and method for using same
US6816605B2 (en) 1999-10-08 2004-11-09 Lumidigm, Inc. Methods and systems for biometric identification of individuals using linear optical spectroscopy
US6563585B1 (en) 1999-11-24 2003-05-13 University Of Maryland Biotechnology Institute Ratiometric fluorometer
US6577884B1 (en) 2000-06-19 2003-06-10 The General Hospital Corporation Detection of stroke events using diffuse optical tomagraphy
DE10020615C2 (en) * 2000-04-27 2002-02-28 Glukomeditech Ag Process for the long-term stable and reproducible spectrometric measurement of the concentrations of the components of aqueous solutions and device for carrying out this process
KR100389906B1 (en) 2001-05-09 2003-07-04 삼성전자주식회사 Apparatus and method for measuring concentration of component in target material
SG126677A1 (en) * 2001-06-26 2006-11-29 Meng Ting Choon Method and device for measuring blood sugar level
US6650915B2 (en) * 2001-09-13 2003-11-18 Fovioptics, Inc. Non-invasive measurement of blood analytes using photodynamics
AU2002365127B2 (en) * 2001-10-02 2008-09-18 Trustees Of Tufts College Self-assembling polymers, and materials fabricated therefrom
US20050010091A1 (en) * 2003-06-10 2005-01-13 Woods Joe W. Non-invasive measurement of blood glucose using retinal imaging
JP4347216B2 (en) 2002-04-22 2009-10-21 マルシオ マルク アブリュー Biological parameter measuring device
US8849379B2 (en) * 2002-04-22 2014-09-30 Geelux Holdings, Ltd. Apparatus and method for measuring biologic parameters
US10123732B2 (en) 2002-04-22 2018-11-13 Geelux Holdings, Ltd. Apparatus and method for measuring biologic parameters
US8328420B2 (en) 2003-04-22 2012-12-11 Marcio Marc Abreu Apparatus and method for measuring biologic parameters
US7738935B1 (en) 2002-07-09 2010-06-15 Pacesetter, Inc. Methods and devices for reduction of motion-induced noise in pulse oximetry
US6997879B1 (en) 2002-07-09 2006-02-14 Pacesetter, Inc. Methods and devices for reduction of motion-induced noise in optical vascular plethysmography
US7620212B1 (en) 2002-08-13 2009-11-17 Lumidigm, Inc. Electro-optical sensor
US6895264B2 (en) * 2002-08-26 2005-05-17 Fovioptics Inc. Non-invasive psychophysical measurement of glucose using photodynamics
US20040115754A1 (en) * 2002-12-11 2004-06-17 Umax Data Systems Inc. Method for establishing a long-term profile of blood sugar level aiding self-control of the same
TW200411178A (en) * 2002-12-31 2004-07-01 Veutron Corp Method for determining the resolution of blood glucose by using rising time curve
KR100464324B1 (en) 2003-03-17 2005-01-03 삼성전자주식회사 Method and apparatus for measuring concentration of constituents in body fluids
US7627151B2 (en) * 2003-04-04 2009-12-01 Lumidigm, Inc. Systems and methods for improved biometric feature definition
US7668350B2 (en) 2003-04-04 2010-02-23 Lumidigm, Inc. Comparative texture analysis of tissue for biometric spoof detection
US7460696B2 (en) 2004-06-01 2008-12-02 Lumidigm, Inc. Multispectral imaging biometrics
US7347365B2 (en) * 2003-04-04 2008-03-25 Lumidigm, Inc. Combined total-internal-reflectance and tissue imaging systems and methods
US7545963B2 (en) 2003-04-04 2009-06-09 Lumidigm, Inc. Texture-biometrics sensor
US7751594B2 (en) 2003-04-04 2010-07-06 Lumidigm, Inc. White-light spectral biometric sensors
KR20060002923A (en) 2003-04-04 2006-01-09 루미다임 인크. Multispectral biometric sensor
US7394919B2 (en) 2004-06-01 2008-07-01 Lumidigm, Inc. Multispectral biometric imaging
US7539330B2 (en) * 2004-06-01 2009-05-26 Lumidigm, Inc. Multispectral liveness determination
TW592667B (en) * 2003-04-04 2004-06-21 Veutron Corp Method for determining the resolution of blood glucose
US20050007582A1 (en) * 2003-07-07 2005-01-13 Lumidigm, Inc. Methods and apparatus for collection of optical reference measurements for monolithic sensors
US7263213B2 (en) 2003-12-11 2007-08-28 Lumidigm, Inc. Methods and systems for estimation of personal characteristics from biometric measurements
KR100634498B1 (en) * 2004-01-12 2006-10-13 삼성전자주식회사 Apparatus and method for measuring constituents of body
US10227063B2 (en) 2004-02-26 2019-03-12 Geelux Holdings, Ltd. Method and apparatus for biological evaluation
KR20060129507A (en) * 2004-03-06 2006-12-15 카리스토 메디컬, 아이엔씨. Methods and devices for non-invasively measuring quantitative information of substances in living organisms
US8229185B2 (en) 2004-06-01 2012-07-24 Lumidigm, Inc. Hygienic biometric sensors
US7508965B2 (en) 2004-06-01 2009-03-24 Lumidigm, Inc. System and method for robust fingerprint acquisition
US20110163163A1 (en) * 2004-06-01 2011-07-07 Lumidigm, Inc. Multispectral barcode imaging
US9341565B2 (en) 2004-07-07 2016-05-17 Masimo Corporation Multiple-wavelength physiological monitor
US7343186B2 (en) 2004-07-07 2008-03-11 Masimo Laboratories, Inc. Multi-wavelength physiological monitor
US8787630B2 (en) 2004-08-11 2014-07-22 Lumidigm, Inc. Multispectral barcode imaging
US7865223B1 (en) * 2005-03-14 2011-01-04 Peter Bernreuter In vivo blood spectrometry
US8055321B2 (en) 2005-03-14 2011-11-08 Peter Bernreuter Tissue oximetry apparatus and method
US7801338B2 (en) 2005-04-27 2010-09-21 Lumidigm, Inc. Multispectral biometric sensors
US7596397B2 (en) * 2005-05-16 2009-09-29 Hutchinson Technology Incorporated Patient interface for spectroscopy applications
US7460897B1 (en) 2005-05-16 2008-12-02 Hutchinson Technology Incorporated Patient interface for spectroscopy applications
US7791728B2 (en) * 2005-08-11 2010-09-07 Hewlett-Packard Development Company, L.P. System for optically analyzing a substance with a selected single-wavelength
KR101370985B1 (en) 2005-10-24 2014-03-10 마시오 마크 아우렐리오 마틴스 애브리우 Apparatus and method for measuring biologic parameters
US8478386B2 (en) 2006-01-10 2013-07-02 Accuvein Inc. Practitioner-mounted micro vein enhancer
US8489178B2 (en) 2006-06-29 2013-07-16 Accuvein Inc. Enhanced laser vein contrast enhancer with projection of analyzed vein data
US11253198B2 (en) 2006-01-10 2022-02-22 Accuvein, Inc. Stand-mounted scanned laser vein contrast enhancer
US11278240B2 (en) 2006-01-10 2022-03-22 Accuvein, Inc. Trigger-actuated laser vein contrast enhancer
US10813588B2 (en) 2006-01-10 2020-10-27 Accuvein, Inc. Micro vein enhancer
US8838210B2 (en) 2006-06-29 2014-09-16 AccuView, Inc. Scanned laser vein contrast enhancer using a single laser
US9492117B2 (en) 2006-01-10 2016-11-15 Accuvein, Inc. Practitioner-mounted micro vein enhancer
US9854977B2 (en) 2006-01-10 2018-01-02 Accuvein, Inc. Scanned laser vein contrast enhancer using a single laser, and modulation circuitry
US8730321B2 (en) 2007-06-28 2014-05-20 Accuvein, Inc. Automatic alignment of a contrast enhancement system
US8594770B2 (en) 2006-06-29 2013-11-26 Accuvein, Inc. Multispectral detection and presentation of an object's characteristics
US8463364B2 (en) 2009-07-22 2013-06-11 Accuvein Inc. Vein scanner
US10238294B2 (en) 2006-06-29 2019-03-26 Accuvein, Inc. Scanned laser vein contrast enhancer using one laser
US8355545B2 (en) 2007-04-10 2013-01-15 Lumidigm, Inc. Biometric detection using spatial, temporal, and/or spectral techniques
CN103336941A (en) 2006-07-19 2013-10-02 光谱辨识公司 Multibiometric multispectral imager
US8175346B2 (en) 2006-07-19 2012-05-08 Lumidigm, Inc. Whole-hand multispectral biometric imaging
US7995808B2 (en) 2006-07-19 2011-08-09 Lumidigm, Inc. Contactless multispectral biometric capture
US7804984B2 (en) 2006-07-31 2010-09-28 Lumidigm, Inc. Spatial-spectral fingerprint spoof detection
US7801339B2 (en) 2006-07-31 2010-09-21 Lumidigm, Inc. Biometrics with spatiospectral spoof detection
WO2008134135A2 (en) 2007-03-21 2008-11-06 Lumidigm, Inc. Biometrics based on locally consistent features
US8577431B2 (en) 2008-07-03 2013-11-05 Cercacor Laboratories, Inc. Noise shielding for a noninvasive device
US20100030040A1 (en) 2008-08-04 2010-02-04 Masimo Laboratories, Inc. Multi-stream data collection system for noninvasive measurement of blood constituents
WO2010056973A1 (en) 2008-11-14 2010-05-20 Nonin Medical, Inc. Optical sensor path selection
US9061109B2 (en) 2009-07-22 2015-06-23 Accuvein, Inc. Vein scanner with user interface
EP2467058A4 (en) * 2009-08-17 2014-08-06 Univ California Distributed external and internal wireless sensor systems for characterization of surface and subsurface biomedical structure and condition
EP2471023A1 (en) 2009-08-26 2012-07-04 Lumidigm, Inc. Multiplexed biometric imaging and dual-imager biometric sensor
US8688183B2 (en) 2009-09-03 2014-04-01 Ceracor Laboratories, Inc. Emitter driver for noninvasive patient monitor
US8570149B2 (en) 2010-03-16 2013-10-29 Lumidigm, Inc. Biometric imaging using an optical adaptive interface
EP2756303B1 (en) * 2011-09-15 2018-08-22 The Trustees of Columbia University in the City of New York Measurement of a fluorescent analyte using tissue excitation
US9907494B2 (en) 2012-04-18 2018-03-06 Hutchinson Technology Incorporated NIRS device with optical wavelength and path length correction
JP2014016230A (en) * 2012-07-09 2014-01-30 National Institute Of Advanced Industrial & Technology Spectroanalysis method for use in-situ observation of organism
US9072426B2 (en) 2012-08-02 2015-07-07 AccuVein, Inc Device for detecting and illuminating vasculature using an FPGA
US10376148B2 (en) 2012-12-05 2019-08-13 Accuvein, Inc. System and method for laser imaging and ablation of cancer cells using fluorescence
CN203289635U (en) 2013-05-10 2013-11-13 瑞声声学科技(深圳)有限公司 Spring plate and multifunctional sounder applying spring plate
CA2980036A1 (en) 2013-10-11 2015-04-16 Marcio Marc Abreu Method and apparatus for biological evaluation
AU2015204638A1 (en) 2014-01-10 2016-07-21 Marcio Marc Abreu Device for measuring the infrared output of the Abreu brain thermal tunnel
CA2936235A1 (en) 2014-01-10 2015-07-16 Marcio Marc Abreu Devices to monitor and provide treatment at an abreu brain tunnel
CN106163463A (en) 2014-01-22 2016-11-23 马尔西奥·马克·阿布雷乌 It is configured to the device processed in ABREU brain fever passage offer
US10213550B2 (en) 2014-01-23 2019-02-26 Covidien Lp Systems and methods for monitoring clinical procedures using regional blood oxygen saturation
US9867561B2 (en) 2014-01-27 2018-01-16 Covidien Lp Systems and methods for determining whether regional oximetry sensors are properly positioned
US9861317B2 (en) 2014-02-20 2018-01-09 Covidien Lp Methods and systems for determining regional blood oxygen saturation
HUE042517T2 (en) 2014-12-23 2019-07-29 Max Planck Gesellschaft Method for measuring a spectral sample response
US10328202B2 (en) 2015-02-04 2019-06-25 Covidien Lp Methods and systems for determining fluid administration
AU2016228998A1 (en) 2015-03-10 2017-09-28 Marcio Marc Abreu Devices, apparatuses, systems, and methods for measuring temperature of an ABTT terminus
JP6323882B2 (en) * 2016-11-15 2018-05-16 国立研究開発法人産業技術総合研究所 Spectroscopic analysis for in situ observation of living body
US20220331028A1 (en) 2019-08-30 2022-10-20 Metralabs Gmbh Neue Technologien Und Systeme System for Capturing Movement Patterns and/or Vital Signs of a Person

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293504A1 (en) * 1987-06-03 1988-12-07 Hewlett-Packard GmbH Method for determining the perfusion
US4819752A (en) * 1987-10-02 1989-04-11 Datascope Corp. Blood constituent measuring device and method
EP0317121A2 (en) * 1987-11-17 1989-05-24 Kurashiki Boseki Kabushiki Kaisha Spectroscopic method and apparatus for measuring sugar concentrations
EP0404562A2 (en) * 1989-06-21 1990-12-27 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
WO1991011136A1 (en) * 1990-02-02 1991-08-08 Boston Advanced Technologies, Inc. Systems for material analysis based on reflectance ratio detection
US5069214A (en) * 1988-12-14 1991-12-03 Gms Engineering Corporation Flash reflectance oximeter
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
US5119814A (en) * 1990-07-25 1992-06-09 Minnich Thomas E Method and apparatus for monitoring blood loss via retinal venous oxygen saturation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3463142A (en) * 1966-07-05 1969-08-26 Trw Inc Blood content monitor
US3638640A (en) * 1967-11-01 1972-02-01 Robert F Shaw Oximeter and method for in vivo determination of oxygen saturation in blood using three or more different wavelengths
US3958560A (en) * 1974-11-25 1976-05-25 Wayne Front March Non-invasive automatic glucose sensor system
US4014321A (en) * 1974-11-25 1977-03-29 March Wayne F Non-invasive glucose sensor system
DE2606991A1 (en) * 1976-02-20 1977-08-25 Nils Dr Med Kaiser DEVICE FOR DETERMINING THE CONTENT OF METABOLIC PRODUCTS IN THE BLOOD
DE2717659C2 (en) * 1977-04-21 1985-11-14 Wirtzfeld, Alexander, Prof. Dr.med., 8195 Egling Pacemaker
US4281645A (en) * 1977-06-28 1981-08-04 Duke University, Inc. Method and apparatus for monitoring metabolism in body organs
GB2033575B (en) * 1978-05-24 1983-03-02 Rolfe P Investigating substances in a patient's bloodstream
US4350163A (en) * 1980-05-29 1982-09-21 Ford Jr Norman C Method and apparatus for analyzing contaminants in aqueous humor
US4408880A (en) * 1981-09-22 1983-10-11 Chugai Seiyaku Kabushiki Kaisha Laser nephelometric system
EP0160768B1 (en) * 1984-05-04 1989-05-03 Kurabo Industries Ltd. Spectrophotometric apparatus for the non-invasive determination of glucose in body tissues
US4655225A (en) * 1985-04-18 1987-04-07 Kurabo Industries Ltd. Spectrophotometric method and apparatus for the non-invasive
US4704029A (en) * 1985-12-26 1987-11-03 Research Corporation Blood glucose monitor
US4714080A (en) * 1986-10-06 1987-12-22 Nippon Colin Co., Ltd. Method and apparatus for noninvasive monitoring of arterial blood oxygen saturation
DE3681175D1 (en) * 1986-11-17 1991-10-02 Hellige Gmbh COMBINATION SENSOR FOR TRANSCUTANEAL DETECTION OF OXYGEN AND CARBON DIOXIDE IN THE BLOOD.
AU608807B2 (en) * 1987-03-03 1991-04-18 Hitoshi Fujii Apparatus for monitoring bloodstream
NO880891L (en) * 1987-03-03 1988-09-05 Elizabeth May Dowling PROCEDURE AND APPARATUS FOR MEASURING OR DETECTING THE CONCENTRATION OF A SUBSTANCE.
US4785814A (en) * 1987-08-11 1988-11-22 Cordis Corporation Optical probe for measuring pH and oxygen in blood and employing a composite membrane
US4796636A (en) * 1987-09-10 1989-01-10 Nippon Colin Co., Ltd. Noninvasive reflectance oximeter
US4854699A (en) * 1987-11-02 1989-08-08 Nippon Colin Co., Ltd. Backscatter oximeter
US4882492A (en) * 1988-01-19 1989-11-21 Biotronics Associates, Inc. Non-invasive near infrared measurement of blood analyte concentrations
US4901728A (en) * 1988-05-31 1990-02-20 Eol, Inc. Personal glucose monitor
US5028787A (en) * 1989-01-19 1991-07-02 Futrex, Inc. Non-invasive measurement of blood glucose
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5007423A (en) * 1989-10-04 1991-04-16 Nippon Colin Company Ltd. Oximeter sensor temperature control
US5054487A (en) * 1990-02-02 1991-10-08 Boston Advanced Technologies, Inc. Laser systems for material analysis based on reflectance ratio detection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293504A1 (en) * 1987-06-03 1988-12-07 Hewlett-Packard GmbH Method for determining the perfusion
US4819752A (en) * 1987-10-02 1989-04-11 Datascope Corp. Blood constituent measuring device and method
EP0317121A2 (en) * 1987-11-17 1989-05-24 Kurashiki Boseki Kabushiki Kaisha Spectroscopic method and apparatus for measuring sugar concentrations
US5069214A (en) * 1988-12-14 1991-12-03 Gms Engineering Corporation Flash reflectance oximeter
EP0404562A2 (en) * 1989-06-21 1990-12-27 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5070874A (en) * 1990-01-30 1991-12-10 Biocontrol Technology, Inc. Non-invasive determination of glucose concentration in body of patients
WO1991011136A1 (en) * 1990-02-02 1991-08-08 Boston Advanced Technologies, Inc. Systems for material analysis based on reflectance ratio detection
US5119814A (en) * 1990-07-25 1992-06-09 Minnich Thomas E Method and apparatus for monitoring blood loss via retinal venous oxygen saturation

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700660A1 (en) * 1994-03-14 1996-03-13 Sony Corporation Blood sugar level measuring apparatus
EP0700660A4 (en) * 1994-03-14 1996-10-23 Sony Corp Blood sugar level measuring apparatus
EP0689848A1 (en) * 1994-06-27 1996-01-03 Commissariat A L'energie Atomique Powder inhaler
FR2721521A1 (en) * 1994-06-27 1995-12-29 Commissariat Energie Atomique Automatic micro-doser medication dispenser device and intelligent dosing set using this device.
DE19612425C2 (en) * 1995-03-31 2000-08-31 Nihon Kohden Corp Apparatus for measuring hemoglobin concentration
US6466807B1 (en) 1997-08-12 2002-10-15 Abbott Laboratories Optical glucose detector
GB2328279B (en) * 1997-08-12 2001-10-10 Abbott Lab Optical glucose detector
GB2328279A (en) * 1997-08-12 1999-02-17 Abbott Lab Three wavelength in-vivo analyte detector
WO2001037722A1 (en) * 1999-11-23 2001-05-31 Forskningscenter Risø A non-invasive method for the measurement of body fluid analytes
US7356365B2 (en) 2003-07-09 2008-04-08 Glucolight Corporation Method and apparatus for tissue oximetry
US7510849B2 (en) 2004-01-29 2009-03-31 Glucolight Corporation OCT based method for diagnosis and therapy
US10130291B2 (en) 2004-08-11 2018-11-20 Masimo Corporation Method for data reduction and calibration of an OCT-based physiological monitor
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
US11426104B2 (en) 2004-08-11 2022-08-30 Masimo Corporation Method for data reduction and calibration of an OCT-based physiological monitor
US10791971B2 (en) 2004-08-11 2020-10-06 Masimo Corporation Method for data reduction and calibration of an OCT-based physiological monitor
US9078560B2 (en) 2004-08-11 2015-07-14 Glt Acquisition Corp. Method for data reduction and calibration of an OCT-based physiological monitor
US9554737B2 (en) 2004-08-11 2017-01-31 Masimo Corporation Noninvasively measuring analyte levels in a subject
US9668679B2 (en) 2004-08-11 2017-06-06 Masimo Corporation Method for data reduction and calibration of an OCT-based physiological monitor
US9060721B2 (en) 2008-03-04 2015-06-23 Glt Acquisition Corp. Flowometry in optical coherence tomography for analyte level estimation
US9833180B2 (en) 2008-03-04 2017-12-05 Masimo Corporation Multispot monitoring for use in optical coherence tomography
US10368787B2 (en) 2008-03-04 2019-08-06 Masimo Corporation Flowometry in optical coherence tomography for analyte level estimation
US11033210B2 (en) 2008-03-04 2021-06-15 Masimo Corporation Multispot monitoring for use in optical coherence tomography
US11426105B2 (en) 2008-03-04 2022-08-30 Masimo Corporation Flowometry in optical coherence tomography for analyte level estimation
US11660028B2 (en) 2008-03-04 2023-05-30 Masimo Corporation Multispot monitoring for use in optical coherence tomography
EP2590563A4 (en) * 2010-07-08 2017-07-19 Glucostats System Pte Ltd Apparatus and method for predicting a parameter in the blood stream of a subject
CN103140169A (en) * 2010-07-08 2013-06-05 格路寇斯特斯系统私人有限公司 Apparatus and method for predicting a parameter in the blood stream of a subject
WO2012005696A1 (en) * 2010-07-08 2012-01-12 Glucostats System Pte Ltd Apparatus and method for predicting a parameter in the blood stream of a subject
RU2770566C1 (en) * 2021-01-15 2022-04-18 ООО "НПП Волга" Method for non-invasive determination of the content of lipids in a person

Also Published As

Publication number Publication date
US5222495A (en) 1993-06-29
AU4806393A (en) 1994-03-15

Similar Documents

Publication Publication Date Title
US5222495A (en) Non-invasive blood analysis by near infrared absorption measurements using two closely spaced wavelengths
US5222496A (en) Infrared glucose sensor
US4975581A (en) Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5054487A (en) Laser systems for material analysis based on reflectance ratio detection
US5617852A (en) Method and apparatus for non-invasively determining blood analytes
US5372135A (en) Blood constituent determination based on differential spectral analysis
US6026314A (en) Method and device for noninvasive measurements of concentrations of blood components
US6615061B1 (en) Optical sensor having a selectable sampling distance for determination of analytes
US5460177A (en) Method for non-invasive measurement of concentration of analytes in blood using continuous spectrum radiation
US7343185B2 (en) Measurement of body compounds
US8406839B2 (en) Method and apparatus for determining blood analytes
KR100893432B1 (en) A method for noninvasive measurement of a target analyte property in a tissue sample and an apparatus therefor
US6741876B1 (en) Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths
EP1478265B1 (en) Active pulse spectrophotometry
EP1498070A1 (en) Noninvasive blood component value measuring instrument and method
EP0630203A1 (en) Non-invasive device and method for determining concentrations of various components of blood or tissue
US5246004A (en) Infrared cholesterol sensor
CA2383725A1 (en) Method for determination of analytes using nir, adjacent visible spectrum and discrete nir wavelengths
WO1991011136A1 (en) Systems for material analysis based on reflectance ratio detection
JP4472794B2 (en) Glucose concentration determination device
EP0623308A1 (en) Method for non-invasive measurement of concentration of constituents in blood
KR100300960B1 (en) Method and device for noninvasive determination of the concentrations of blood components
JPH10179557A (en) Bio measurement device and bio measurement method
Céelleri et al. Non-Invasive Blood Sugar Measurement System
WO1996013203A1 (en) Non-invasive measurement of analytes in blood

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA